Halamka offers initial response to MACRA proposed rule

The MACRA proposed rule is "an example of regulatory overambition," according to John Halamka, MD, CIO of Beth Israel Deaconess Medical Center in Boston.

Writing in a blog post, Halamka said many of the concepts are good, such as reducing documentation burden, enabling flexbility, focusing on outcomes/quality, engaging patients in novel ways, and emphasizing connectivity/interoperability. However, he questions the use of ONC's 2015 Certification Rule because it will have the following three "bad consequences":

  • The burden of certification will consume developer resources that could be used for innovation
  • The standards listed in the certification rule have varying degrees of maturity and we'll be setting in concrete some technologies that should not be used
  • The certification rule did not envision the kinds of products or services the private sector would develop between 2016 and 2018

"The 2015 Rule is a kitchen sink of standards, many of which are not ready for production deployment," he wrote, calling instead for use of the Standards Advisory concept to provide a constrained list of standards but then let vendors innovate as needed to support the workflows desired by patients, clinicians and hospitals."  

Halamka applauds the focus on outcomes and quality, he wrote. "Meaningful Use has run its course and achieved its goals. It needs to be replaced. Along with replacing Meaningful Use, let's rethink the certification concept too."

He promised a more thorough review of the proposed rule in coming days.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.